10-K: Sonoma Pharmaceuticals Reports Continued Losses and Going Concern Doubt Amidst Revenue Growth and Strategic Partnerships in Fiscal Year 2025

Sonoma Pharmaceuticals, Inc. reported a net loss of $3.457 million for fiscal year 2025, despite a 12% increase in total revenue to $14.288 million, raising substantial doubt about its ability to continue as a going concern.

Summary

• Sonoma Pharmaceuticals reported a net loss of $3.457 million for the fiscal year ended March 31, 2025, an improvement from a net loss of $4.835 million in the prior fiscal year.
• Total revenue increased by 12% to $14.288 million in FY2025, up from $12.735 million in FY2024, driven by expansion of distribution networks, new product introductions, and organic growth.
• Gross profit rose by 15% to $5.465 million in FY2025, maintaining a consistent gross profit margin of 38%.
• Operating expenses decreased by 3% to $9.175 million in FY2025, attributed to ongoing cost containment efforts.
• Cash and cash equivalents increased to $5.374 million as of March 31, 2025, compared to $3.128 million in the prior year.
• The company's accumulated deficit reached $197.806 million as of March 31, 2025.
• Net cash used in operating activities significantly reduced to $88,000 in FY2025 from $2.398 million in FY2024.
• The independent auditor's report highlights substantial doubt about the company's ability to continue as a going concern due to historical losses and negative operating cash flows.
• International sales accounted for approximately 82% of total revenue in FY2025, indicating a strong reliance on foreign markets.
• Customer concentration remains a factor, with Customer B representing 21% and Customer C representing 18% of net revenues in FY2025.

Sentiment

Score: 3

Explanation: While the company showed revenue growth and reduced net loss, the persistent losses, accumulated deficit, and explicit 'going concern' doubt from auditors indicate a precarious financial position. The need for future capital raises and significant tax liabilities in Mexico further weigh down the sentiment, despite positive product developments and regulatory clearances.

Positives

• Total revenue increased by 12% to $14.288 million in FY2025, demonstrating continued expansion of distribution and customer base.
• Net loss decreased to $3.457 million in FY2025 from $4.835 million in FY2024, indicating progress in reducing losses.
• Gross profit increased by 15% to $5.465 million, with a stable gross profit margin of 38%.
• Operating expenses decreased by 3% due to ongoing cost containment efforts across the company.
• Successful transition of all commercialized products in Europe to the new EU Medical Device Regulation (MDR), ensuring continued market access.
• Manufacturing facility and five products successfully registered with the Medicines & Healthcare products Regulatory Agency (MHRA) in the United Kingdom.
• New partnerships established with WellSpring Pharmaceutical Corporation for US retail sales and Medline Industries, LP for wound care product distribution in the US and Canada.
• Received two new 510(k) clearances from the FDA for specific over-the-counter indications and improved biocompatibility of Microcyn-based products.
• Relaunched prescription eye care product Acuicyn and several prescription dermatology products (Celacyn, Levicyn, Epicyn) and OTC products (Lasercyn Dermal Spray, Lasercyn Gel).
• Nanocyn Disinfectant & Sanitizer received extended claims approval in Australia for Candida auris and Clostritium Difficile, and additional EPA approvals in the US for emerging viral pathogens and various bacteria/fungi.
• Nanocyn also received Green Seal Certification, highlighting its eco-certified, all-natural disinfectant status.
• Net cash used in operating activities significantly reduced to $88,000 in FY2025 from $2.398 million in FY2024, indicating improved cash management from operations.
• Cash and cash equivalents increased to $5.374 million as of March 31, 2025, providing a stronger liquidity position.
• Management has remediated material weaknesses in internal control over financial reporting, including hiring experienced financial staff and implementing improved controls.

Negatives

• The company reported a net loss of $3.457 million for FY2025 and has an accumulated deficit of $197.806 million, indicating a history of unprofitability.
• The independent auditor's report explicitly states 'substantial doubt about its ability to continue as a going concern' due to significant losses and negative operating cash flows.
• Working capital slightly decreased from $8.829 million in FY2024 to $8.552 million in FY2025.
• Heavy reliance on a few key customers, with Customer B (21%) and Customer C (18%) representing significant portions of net revenues in FY2025, posing a risk if these relationships are disrupted.
• Mexican tax law prevents the deduction of intercompany interest expense incurred by the Mexico subsidiary and requires withholding tax on payments remitted to the US, while the company cannot recognize foreign tax credits due to substantial US net operating losses.
• The Mexico subsidiary owes approximately $10.9 million in principal, $8.6 million in technical assistance payments, and $26.4 million in accrued interest on intercompany loans, maturing in 2027, with potential tax liabilities of $13.8 million if debt is forgiven/converted and $5.1 million in withholding tax if interest/technical assistance is repaid.
• Exposure to foreign currency exchange rate fluctuations, particularly for the Mexican Peso and Euro against the US dollar, which can negatively impact revenues and operating results.
• Certain products (Sinudox, Microdacyn Oral, MucoClyns) will not be transitioned to the new EU Medical Devices Regulation without additional studies, and the company is evaluating whether to conduct these studies, potentially limiting market access for these products.
• The company operates in highly competitive markets against larger entities with greater financial resources, name recognition, and established distribution networks, which can offer competitive advantages like rebates or bundled products.

Risks

• The company has a history of losses and expects to continue incurring losses, with its March 31, 2025, financial statements including disclosure that casts substantial doubt regarding its ability to continue as a going concern.
• The company must raise additional capital to pursue product development initiatives, penetrate markets, and continue as a going concern, with no assurance that such capital will be available on commercially acceptable terms.
• Dependence on third-party distributors and strategic partners means limited control over their resources and potential for breaches or terminations of agreements, which could delay or prevent product commercialization.
• Mexican tax law prevents the deduction of intercompany interest expense and requires withholding tax on payments to the US, while the company is unable to recognize foreign tax credits for US tax purposes, leading to significant tax liabilities.
• Reliance on a small number of key customers for a significant portion of revenues means the loss of any of these customers could adversely affect revenues.
• A majority of the company's business is conducted outside the United States, exposing it to additional risks such as local political/economic instability, exchange rate changes, regulatory changes, trade restrictions, and difficulties in collecting accounts receivables.
• Failure to obtain, or significant delays in obtaining, additional regulatory clearances or approvals (e.g., FDA 510(k), EU MDR) for current or future products could prevent commercialization.
• Failure to comply with ongoing regulatory requirements or unanticipated problems with products could lead to restrictions or withdrawal from the market, including costly recalls.
• New government regulations or changes in FDA policies, their interpretation, and enforcement could prevent or delay regulatory approval of products.
• If third-party contractors fail to perform their responsibilities or comply with FDA rules, the manufacture, marketing, and sales of products could be delayed.
• Product recalls, whether voluntary or mandated by regulatory bodies, could result in substantial expenditures, lost revenues, and adverse public relations.
• If products do not gain market acceptance due to factors like price, perceived effectiveness, or marketing efforts, the company may not be able to fund future operations.
• Competitors developing less expensive or more effective products with similar characteristics to the company's HOCl technology could reduce or eliminate its commercial opportunity.
• The success of research and development efforts depends on the ability to find suitable collaborators, and unsuccessful collaborations could adversely affect results.
• Failure to comply with broad and complex federal and state healthcare fraud and abuse laws (e.g., Anti-Kickback Statute, False Claims Act, HIPAA) could lead to substantial penalties and exclusion from government healthcare programs.
• The company may not be able to maintain sufficient product liability insurance to cover potential claims, which could have a material adverse effect.
• Revenue generation will be diminished if partners are unable to obtain acceptable prices or adequate reimbursement from third-party payors, or if they face pricing pressure and customer product substitutions.
• The company's information technology and infrastructure may be breached or attacked, exposing it to liability, damaging its reputation, or compromising confidential information.
• Cash and cash equivalents are maintained in balances exceeding current FDIC insurance limits, exposing the company to the risk of banking institution failure.
• The market price of the company's common stock may be volatile, and the value of investments could decline significantly.
• Anti-takeover provisions in the company's corporate documents and Delaware law may make it more difficult for stockholders to change management or resist a takeover.
• Stockholders may experience substantial dilution in the value of their investment if the company issues additional shares of capital stock or other securities convertible into common stock.
• Shares issuable upon the exercise of outstanding options may substantially increase the number of shares available for sale in the public market and depress the price of common stock.
• Failure to maintain compliance with Nasdaq's continued listing requirements could result in the delisting of the company's common stock.

Future Outlook

Sonoma Pharmaceuticals expects to continue incurring losses for the foreseeable future and must raise additional capital to pursue product development, penetrate markets, and sustain operations. The company anticipates recognizing approximately $350,000 in income related to employee retention credits in fiscal 2026. Management believes current assets are sufficient to cover Mexico tax obligations without interrupting operations and is exploring options to limit exposure to these amounts. The company plans to continue marketing and selling products internationally and may establish additional manufacturing facilities with geographic expansion. The company will continue to evaluate its deferred tax assets to determine whether any changes in circumstances could affect the realization of their future benefit.

Management Comments

• "Over the past year, we have continued our focus on increasing revenues and continuing progress towards profitability."
• "During our most recent fiscal year, our revenues have grown as a result of continued expansion of our distribution network and customer base, the introduction of new products into multiple markets around the world, as well as organic growth from existing customers and distributors."
• "We have also focused on expanding and strengthening our regulatory reach by seeking new approvals and clearances."
• "We continue to invest in research and development, both in the U.S. and internationally, for our core performance-stabilized hypochlorous acid, or HOCl, technology."
• "We have an active pipeline of products and we intend to continue to seek new regulatory clearances to expand potential markets for our products."
• "We believe we own or have access to sufficient factory space and equipment to produce an adequate amount of product to meet anticipated future requirements for at least the next two years."
• "Management believes that the Company has access to additional capital resources through possible public or private equity offerings, debt financings, corporate collaborations or other means."
• "Management believes there are sufficient assets on the balance sheet to cover any tax obligation without interrupting our operations or business."
• "We have engaged tax professionals to review all options to limit our exposure to these amounts and to proceed in a manner that is most advantageous to us."
• "We also closely monitor global economic conditions, including the risk of economic downturn or recession, the prospect of new or increased tariffs, as well as overall consumer sentiment, any of which may impact our financial results."
• "We currently do not anticipate that a material amount will be purchased for the year ended March 31, 2026 [for capital expenditures]."
• "We believe we have taken steps to correct this [material weaknesses in internal control] and the controls have been working for a sufficient period of time to remove this weakness."
• "We remain committed to an effective internal control environment, and management believes that these actions and the improvements management expects to achieve as a result effectively remediated the material weaknesses."

Industry Context

Sonoma Pharmaceuticals operates in the highly competitive global healthcare market, specifically in dermatology, eye, nasal and oral care, wound and acute care, podiatry, animal health care, and surface disinfectants. The company leverages its proprietary stabilized hypochlorous acid (HOCl) technology, claiming superior stability, efficacy, and safety compared to traditional treatments like corticosteroids, topical steroids, and antibiotics, which may have side effects or resistance issues. However, it faces significant competition from larger pharmaceutical and biotechnology companies that possess greater financial resources, established distribution networks, and broader product lines, enabling them to offer competitive pricing and bundled discounts. The industry is subject to extensive and evolving government regulations, including FDA clearances in the US and the new EU Medical Devices Regulation (MDR) in Europe. There is increasing pressure from third-party payors to control healthcare costs, which impacts product pricing and reimbursement, and a trend towards managed healthcare and patient cost-shifting, favoring lower-cost alternatives.

Management Changes

Corporate Governance

Legal Proceedings

• The company may be involved in legal matters arising in the ordinary course of business, including matters involving proprietary technology.
• While management believes such matters are currently insignificant, any litigation could have a material adverse effect on the company's business, financial condition, or results of comprehensive (loss) income.

Related Party Transactions

• As of March 31, 2025, the company's Mexico subsidiary (Oculus Technologies of Mexico, S.A. de C.V.) owes approximately $10.9 million in principal, $8.6 million in technical assistance payments, and $26.4 million in accrued interest on intercompany loans, which mature in 2027.
• Mexican tax law prevents the deduction of intercompany interest on the Mexico subsidiary's tax returns since 2004, and any interest paid to a foreign lender is subject to a 15% Mexico withholding tax.
• The company also has interest owed on its intercompany technical assistance agreement and a 10% royalty withholding on this agreement, amounting to approximately $5.1 million in Mexico withholding tax as of March 31, 2025, if all amounts were repaid.
• Due to substantial U.S. net operating losses, the company is prevented from claiming any credit on any withholding tax for U.S. income tax purposes related to these intercompany transactions.

Stakeholder Impact

• Shareholders face significant risks including potential dilution from future capital raises, volatility in stock price, and the substantial doubt about the company's ability to continue as a going concern. The complex Mexican tax liabilities also pose a financial risk.
• Employees are subject to the company's financial performance and potential cost reduction measures if additional capital is not secured. They also benefit from equity incentive plans and are governed by updated conduct policies.
• Customers may benefit from new product introductions and expanded distribution networks, but could be impacted by product recalls or supply chain disruptions. They may also face product substitutions due to pricing pressures.
• Suppliers' business relationships could be affected by the company's financial health and any operational curtailments.
• Creditors, particularly those involved in the intercompany loans to the Mexico subsidiary, face exposure due to the company's history of losses and the going concern doubt, as well as the complex tax implications of these loans.

Next Steps

• Continue efforts to commercialize existing products and expand sales and marketing initiatives.
• Seek new regulatory clearances to expand potential markets for products, leveraging the active pipeline of HOCl technology.
• Evaluate whether to conduct additional studies necessary to transition products like Sinudox, Microdacyn Oral, and MucoClyns to the new EU Medical Devices Regulation.
• Engage tax professionals to review all options to limit exposure to the substantial Mexico tax liabilities related to intercompany debt and technical assistance payments.
• Monitor global economic conditions, including the risk of economic downturn or recession, the prospect of new or increased tariffs, and overall consumer sentiment.
• Potentially raise additional capital through public or private equity offerings, debt financings, or corporate collaborations to sustain operations and meet obligations.
• Consider establishing additional manufacturing facilities to better serve new geographic markets as part of international expansion plans.
• File the definitive proxy statement for the 2025 annual meeting of stockholders, incorporating information on directors, executive compensation, security ownership, and related party transactions.
• Issue equity awards of 13,500 Restricted Stock Units (RSUs) to Ms. Trombly, Mr. Dvonch, and Mr. Thornton on June 19, 2025, which will vest on the third anniversary of the grant date or upon change of control.

Key Dates

Recommendation

Keywords

Hypochlorous Acid, HOCl, Medical Devices, Wound Care, Dermatology, Eye Care, Animal Health, Disinfectants, SEC Filing, 10-K, Financial Report, Going Concern, Revenue Growth, Net Loss, Regulatory Approval, FDA, CE Mark, Nasdaq, Distribution Agreements, Intellectual Property, Risk Management, Corporate Governance, Biotechnology, Healthcare, Pharmaceuticals